camrelizumab、rivoceranib
Showing 1 - 1 of 1
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Recruiting
- Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Camrelizumab、Rivoceranib
- Camrelizumab
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Jan 4, 2023